Clinical Trials Logo
  1. Home
  2. Primary Breast Cancer
  3. NCT01033162

Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care

Primary Breast Cancer Clinical Trial

Official title:
Using Technology to Enhance Cancer Communication and Improve Clinical Outcome: Effectiveness of the CHESS Ehealth Cancer Support Intervention in Population-Based Care Study

Clinical Trial Summary

The study's aim is to provide information about the clinical and business cases for comprehensive interactive cancer communication systems (ICCS) in the context of real world use for cancer care.

This study will be conducted within the Kaiser Permanente Northwest (KPNW) healthcare system. Outcomes for this study include amount of ICCS use and women's ratings of cancer information competence, perceived social support, and emotional well being. Secondary outcomes will include healthcare utilization, cost-effectiveness, and clinician ratings of healthcare visits.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01033162
Study type Interventional
Source University of Wisconsin, Madison
Contact
Status Completed
Phase N/A
Start date November 2009
Completion date August 2013
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05923177 - Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 Phase 1
Recruiting NCT03270007 - Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy Phase 4
Completed NCT00527449 - Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel Phase 2
Completed NCT04468113 - Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy
Recruiting NCT03711877 - Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study) Phase 3
Active, not recruiting NCT01019616 - Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy Phase 3
Completed NCT01314833 - Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy Phase 3
Completed NCT04127019 - Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) Phase 3
Terminated NCT00172068 - Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow Phase 2
Completed NCT01049425 - Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer Phase 3
Recruiting NCT01840293 - Breast Cancer Proteomics and Molecular Heterogeneity
Completed NCT01779479 - Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) Phase 2
Completed NCT04277338 - Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3 Phase 1
Recruiting NCT05445050 - mULM to Support Breast Cancer Diagnosis and Therapy N/A
Completed NCT00793377 - Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer Phase 3